Jeet Mahal
Chief Operating Officer chez JASPER THERAPEUTICS, INC.
Fortune : 734 264 $ au 31/03/2024
Profil
Jeet Mahal is currently the Chief Operating Officer at Jasper Therapeutics, Inc. Prior to his current position, he held the role of Director-Business & New Product Development at Johnson & Johnson, Scios, Inc., and COR Therapeutics, Inc. He also served as the Vice President-Strategic Marketing at Portola Pharmaceuticals LLC from 2008 to 2019.
Mr. Mahal holds an MBA from Duke University and The Fuqua School of Business.
He also has a graduate degree from the Illinois Institute of Technology and North Carolina State University, as well as an undergraduate degree from the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/03/2024 | 25 009 ( 0,17% ) | 734 264 $ | 31/03/2024 |
Postes actifs de Jeet Mahal
| Sociétés | Poste | Début |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Chief Operating Officer | 21/03/2022 |
Anciens postes connus de Jeet Mahal
| Sociétés | Poste | Fin |
|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2019 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Corporate Officer/Principal | - |
Formation de Jeet Mahal
| Duke University | Masters Business Admin |
| Illinois Institute of Technology | Graduate Degree |
| North Carolina State University | Graduate Degree |
| University of California, Berkeley | Undergraduate Degree |
| The Fuqua School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| JASPER THERAPEUTICS, INC. | Finance |
| Entreprise privées | 3 |
|---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
